Congenital Adrenal Hyperplasia Market

Key Findings

  • The Congenital Adrenal Hyperplasia diagnosed prevalence in the 7MM countries was estimated to be close to 73,000 cases in 2021.
  • The Congenital Adrenal Hyperplasia market size in the seven major markets was approximately USD 21 million in 2021, which is expected to grow by 2032.
  • Some of the key companies in the Congenital Adrenal Hyperplasia (CAH) Market include Neurocrine Biosciences, Diurnal Limited, Spruce Biosciences, Adrenas Therapeutics, Millendo Therapeutics, and others.

 

Request for sample pages to learn more about the market CAGR and key trends Congenital Adrenal Hyperplasia (CAH) Market

 

DelveInsight’s ‘Congenital Adrenal Hyperplasia (CAH) – Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of congenital adrenal hyperplasia (CAH) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

The congenital adrenal hyperplasia (CAH) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted congenital adrenal hyperplasia (CAH) market size from 2019 to 2032, segmented by seven major markets. The report also covers the current congenital adrenal hyperplasia (CAH) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Congenital Adrenal Hyperplasia (CAH): Disease Understanding and Treatment Algorithm

Congenital Adrenal Hyperplasia (CAH) Overview

Congenital adrenal hyperplasia (CAH) is a group of rare inherited autosomal recessive disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. CAH affects the adrenal glands located at the top of each kidney. Normally, the adrenal glands are responsible for producing three different hormones: corticosteroids, mineralocorticoids, and androgens.

 

  • Corticosteroids: steroid hormones that gauge the body’s response to illness or injury
  • Mineralocorticoids: steroid hormones that regulate salt and water levels
  • Androgens: male sex hormones

 

An enzyme deficiency will make the body unable to produce one or more of these hormones, resulting in the overproduction of another type of hormone precursor to compensate for the loss.

 

The most common cause of CAH is the absence of the enzyme 21-hydroxylase. Different mutations in the gene responsible for 21-hydroxylase result in different enzyme levels, producing a spectrum of effects. CAH due to 21-hydroxylase deficiency is responsible for 95% of all cases of CAH and is broken down further into two subcategories: classical CAH, which can be sub-divided into the salt-losing form or the simple-virilizing form, and non-classical CAH. Classical CAH is by far the more severe form and can result in adrenal crisis and death if not detected and treated. Non-classical CAH is milder and may or may not present symptoms. Since the absence of 21-hydroxylase makes the individuals unable to make the hormone cortisol and, in the case of salt-losing CAH, aldosterone, the body produces more androgens which cause a variety of symptoms, such as abnormal genital development in infant girls. There are other much rarer forms of CAH as well, including 11-Beta hydroxylase deficiency, 17a-hydroxylase deficiency, 3-Beta-hydroxysteroid dehydrogenase deficiency, congenital lipoid adrenal hyperplasia, and p450 oxidoreductase deficiency which all present different symptoms. Although CAH is not curable, as long as patients receive adequate care and treatment, they can go on to lead normal lives.

 

The goal of medical treatment of CAH differs by the patient’s age. CAH is a recessive gene, so both the mother and father must be recessive carriers. Couples with recessive CAH genes may prevent CAH through preimplantation genetic diagnosis.

 

During infancy and childhood, treatment aims to prevent adrenal crises and early virilization, promote normal growth, and avoid electrolyte abnormalities and dehydration. In adolescents and adults, treatment aims to achieve normal reproductive function and fertility while avoiding chronic complications of medication insufficiency or excess, including Cushing syndrome.

 

Congenital Adrenal Hyperplasia (CAH) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the congenital adrenal hyperplasia (CAH) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

The DelveInsight congenital adrenal hyperplasia (CAH) Market Report gives a thorough understanding of congenital adrenal hyperplasia (CAH) by including details of disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for congenital adrenal hyperplasia (CAH) in the US, Europe, and Japan.

Congenital Adrenal Hyperplasia (CAH) Epidemiology

The congenital adrenal hyperplasia (CAH) epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed incident patient pool, trends, and assumptions.

 

Key Findings

The disease epidemiology covered in the report provides historical and forecasted congenital adrenal hyperplasia (CAH) epidemiology segmented as the Diagnosed Prevalence of Congenital adrenal hyperplasia, Age-specific cases of Congenital adrenal hyperplasia, Mutation based cases of Congenital adrenal hyperplasia,  and Type-specific cases of Congenital adrenal hyperplasia. The report includes the diagnosed prevalent scenario of congenital adrenal hyperplasia (CAH) symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Congenital Adrenal Hyperplasia (CAH) Market Assessment and Epidemiology Forecast

Country-Wise Congenital Adrenal Hyperplasia (CAH) Epidemiology

The epidemiology segment also provides the congenital adrenal hyperplasia (CAH) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The diagnosed prevalence of congenital adrenal hyperplasia (CAH) population in the 7MM countries was estimated to be close to 73,000 cases in 2021.

Congenital Adrenal Hyperplasia (CAH) Drug Chapters

The drug chapter segment of the congenital adrenal hyperplasia (CAH) report encloses the detailed analysis of congenital adrenal hyperplasia (CAH) marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps understand the congenital adrenal hyperplasia (CAH) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Currently, there is no cure for CAH. However, treatments are available to address some of the associated symptoms. Hitherto, Glucocorticoid therapy (Prednisone, Dexamethasone) is aimed to replace the missing steroids and lead to a reduction in adrenal androgens levels, thus promoting the prevention of virilization, menstrual and reproductive function disorders. The choice of an adequate therapeutic dose is based on the 17-OHP physiological range for a certain age. At times of stress, the dose of glucocorticoids given should be increased. Female patients with classic forms of CAH require lifelong glucocorticoids intake. The non-classical form does not always require treatment, and many women have no disease symptoms throughout their lives. The indication for diagnosis and treatment of this form quite often comes to infertility. The dose of the glucocorticoids given is significantly lower in the treatment of non-classical forms compared to those required during the treatment of classic forms.

Products detail in the report…

 

Congenital Adrenal Hyperplasia (CAH) Emerging Drugs

To meet the current demands of the patient pool and to counter the unmet needs of the therapeutic market, drug developers are gradually shifting their attention toward CAH as a possible indication for new targeted therapies.

 

Several companies are working robustly on many new therapies, such as Crinecerfont (Neurocrine Biosciences), Tildacerfont (Spruce Biosciences), AAV BBP-631 (Adrenas Therapeutics), Chronocort (Diurnal Limited). The mid-stage pipeline is crowded, with several potential therapies with the imminent attention of big pharmaceutical companies for this market space.

 

Crinecerfont (Neurocrine Biosciences), is a potent, selective, orally active corticotropin-releasing factor1, or CRF1, receptor antagonist as demonstrated in a range of in vitro and in vivo assays. CRF1 is a hypothalamic hormone released directly into the hypophyseal portal vasculature, which acts on the CRF1 receptor, a G protein-coupled receptor, or GPCR, in the anterior pituitary to stimulate the release of adrenocorticotropin hormone or ACTH. The primary role of ACTH is the stimulation of the synthesis and release of adrenal steroids, including cortisol. Cortisol from the adrenals has a negative feedback role at the level of the hypothalamus that decreases CRF1 release as well as at the level of the pituitary to inhibit the release of ACTH. This tight control loop is known as the hypothalamic-pituitary-adrenal axis. Blockade of CRF1 receptors at the pituitary has been shown to decrease the release of ACTH, which decreases the production of adrenal steroids, including androgens, and potentially the symptoms associated with classic CAH. Lower ACTH levels would also reduce the amount of exogenous corticosteroid necessary for classic CAH patients to thrive, avoiding the associated side effects of excessive steroid therapy.

 

It has been granted orphan drug designation for the treatment of classic CAH in the US and the EU.

 

The drug is currently being evaluated in Phase III to evaluate the safety and efficacy of crinecerfont in adult patients and pediatric patients with classic CAH.

 

Tildacerfont (Spruce Biosciences) is a CRF1 receptor antagonist designed to potentially offer markedly improved disease control and reduced steroid burden in patients with classic CAH and other diseases characterized by elevated levels of adrenocorticotropic hormone (ACTH). Tildacerfont binds to CRF1 receptors on the pituitary gland, inhibiting excessive production of ACTH, and ultimately limiting the production of adrenal androgens such as androstenedione, a precursor to testosterone.

 

Tildacerfont has been evaluated in eight clinical trials in 235 patients, including two Phase II clinical trials in patients with classic CAH: a 2-week proof of mechanism dose-ranging trial and a 12-week proof of concept trial. In the 12-week trial, tildacerfont treated patients with elevated adrenal androgens at baseline and achieved robust reductions in disease driving hormones, with many patients in the study achieving normal levels of these hormones.

 

It has been granted orphan drug status by both the US FDA and the EMA to treat classic CAH.

 

Currently, it is in late-stage trials for the treatment of adult classic CAH, with a Phase II trial planned in pediatric CAH. Tildacerfont may also benefit patients with other disorders in which elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH) occur, including a rare form of polycystic ovary syndrome (PCOS).

Products detail in the report…

Congenital Adrenal Hyperplasia (CAH) Market Outlook

The congenital adrenal hyperplasia (CAH) market outlook of the report builds a detailed comprehension of the historical, current, and forecasted congenital adrenal hyperplasia (CAH) market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

 

This segment gives a thorough detail of the congenital adrenal hyperplasia (CAH) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the congenital adrenal hyperplasia (CAH) market in the 7MM is expected to change in the study period 2019–2032.

Congenital Adrenal Hyperplasia (CAH) Market Outlook

Key Findings

This section includes a glimpse of the congenital adrenal hyperplasia (CAH) market in the 7MM. Congenital adrenal hyperplasia (CAH) market size in the seven major markets was approximately USD 21 million in 2021.

 

The United States: Market Outlook

This section provides the total congenital adrenal hyperplasia (CAH) market size and market size by congenital adrenal hyperplasia (CAH) therapies in the United States.

 

CAH refers to a group of genetic disorders that affect the body’s adrenal glands. It occurs when the adrenal glands cannot produce these hormones properly, resulting in a hormone imbalance. A deficiency of the 21-hydroxylase enzyme causes more than 90–95% of CAH cases. When this enzyme is missing or present at low levels, the adrenal glands cannot produce two critical hormones, cortisol, and aldosterone. The body responds to this deficiency by producing an excess of male sex hormones, called androgens. Collectively, the excess androgen production and hormone deficiencies can lead to various medical problems, which vary in severity depending on the form of CAH. There are two major forms of 21-hydroxylase-deficient CAH: classic CAH and non-classic CAH.

 

The United States accounts for the highest market size of congenital adrenal hyperplasia (CAH) compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

EU-5 Countries: Market Outlook

The total congenital adrenal hyperplasia (CAH) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

 

Japan Market Outlook

The total congenital adrenal hyperplasia (CAH) market size and market size by therapies of congenital adrenal hyperplasia (CAH) in Japan are also mentioned.

Congenital Adrenal Hyperplasia (CAH) Market Assessment

Congenital Adrenal Hyperplasia (CAH) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers congenital adrenal hyperplasia (CAH) market uptake by drugs, patient uptake by therapies, and sales of each drug. 

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Congenital Adrenal Hyperplasia (CAH) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses congenital adrenal hyperplasia (CAH)’s key players involved in developing targeted therapeutics.

 

Major players include Neurocrine Biosciences, Diurnal Limited, Spruce Biosciences, and others whose key products are expected to get launched in the US market in the coming years.

 

Congenital Adrenal Hyperplasia Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for congenital adrenal hyperplasia (CAH) emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the congenital adrenal hyperplasia (CAH) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or congenital adrenal hyperplasia (CAH) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the congenital adrenal hyperplasia (CAH) market using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD 21 Million in 2021

Key Companies

Neurocrine Biosciences, Diurnal Limited, Spruce Biosciences, Adrenas Therapeutics, Millendo Therapeutics, and others

Scope of the Report

  • The report covers the descriptive overview of congenital adrenal hyperplasia (CAH), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight is provided into the congenital adrenal hyperplasia (CAH) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for congenital adrenal hyperplasia (CAH) is provided, along with the assessment of new therapies, which will impact the current treatment landscape
  • A detailed review of the congenital adrenal hyperplasia (CAH) market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global congenital adrenal hyperplasia (CAH) market

Report Highlights

  • In the coming years, the congenital adrenal hyperplasia (CAH) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence congenital adrenal hyperplasia (CAH) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for congenital adrenal hyperplasia (CAH). The launch of emerging therapies will significantly impact the congenital adrenal hyperplasia (CAH) market.
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for congenital adrenal hyperplasia (CAH).
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Congenital Adrenal Hyperplasia (CAH) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Congenital adrenal hyperplasia (CAH) Pipeline Analysis
  • Congenital adrenal hyperplasia (CAH) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Congenital Adrenal Hyperplasia (CAH) Report Key Strengths

  • 11-year Forecast
  • 7MM Coverage
  • Congenital adrenal hyperplasia (CAH) Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Congenital Adrenal Hyperplasia (CAH) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness

Key Questions

Market Insights:

  • What was the market share (%) distribution in 2019, and how would it look in 2032?
  • What would be the congenital adrenal hyperplasia (CAH) total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest congenital adrenal hyperplasia (CAH) market Size during the forecast period (2019–2032)?
  • At what CAGR is the congenital adrenal hyperplasia (CAH) market expected to grow in the 7MM during the forecast period (2019–2032)?
  • What would be the congenital adrenal hyperplasia (CAH) market outlook across the 7MM during the forecast period (2019–2032)?
  • What would be the congenital adrenal hyperplasia (CAH) market growth till 2032 and the resultant market Size in the year 2032?
  • How would the future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of congenital adrenal hyperplasia (CAH)?
  • What is the historical patient pool of congenital adrenal hyperplasia (CAH) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Congenital adrenal hyperplasia (CAH) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to congenital adrenal hyperplasia (CAH)?
  • Out of all 7MM countries, which country would have the highest diagnosed prevalence of congenital adrenal hyperplasia (CAH) during the forecast period (2019–2032)?
  • At what CAGR is the population expected to grow in the 7MM during the forecast period (2019–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of congenital adrenal hyperplasia (CAH)?
  • What are the current treatment guidelines for treating congenital adrenal hyperplasia (CAH) in the US, Europe, and Japan?
  • What are the congenital adrenal hyperplasia (CAH) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies to treat congenital adrenal hyperplasia (CAH)?
  • How many therapies are developed by each company for the treatment of congenital adrenal hyperplasia (CAH)?
  • How many emerging therapies are in the mid-stage and late stages of development to treat congenital adrenal hyperplasia (CAH)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the congenital adrenal hyperplasia (CAH) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies for congenital adrenal hyperplasia (CAH) and its status?
  • Which key designations have been granted for the emerging therapies for congenital adrenal hyperplasia (CAH)?
  • What are the global historical and forecasted markets for congenital adrenal hyperplasia (CAH)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the congenital adrenal hyperplasia (CAH) market
  • To understand the future market competition in the congenital adrenal hyperplasia (CAH) market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for congenital adrenal hyperplasia (CAH) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the congenital adrenal hyperplasia (CAH) market.
  • To understand the future market competition in the congenital adrenal hyperplasia (CAH) market.

Frequently Asked Questions

What is Congenital Adrenal Hyperplasia?
Congenital adrenal hyperplasia (CAH) is a group of rare inherited autosomal recessive disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. CAH affects the adrenal glands located at the top of each kidney. Normally, the adrenal glands are responsible for producing three different hormones: corticosteroids, mineralocorticoids, and androgens
What is the Congenital Adrenal Hyperplasia Market Size in 7MM?
The Congenital Adrenal Hyperplasia Market Size in the 7MM was found to be USD 21 Million in 2021
At what CAGR is the Congenital Adrenal Hyperplasia Market expected to grow by 2032?
The Congenital Adrenal Hyperplasia Market size was USD 21 Million in 2021 and is expected to grow at a significant CAGR by 2032, estimates DelveInsight
What are the total diagnosed prevalence of Congenital Adrenal Hyperplasia (CAH) in the 7MM?
The diagnosed prevalence of congenital adrenal hyperplasia (CAH) population in the 7MM countries was estimated to be 73,000 cases in 2021
Which country will grab the maximum Congenital Adrenal Hyperplasia Market share among the 7MM?
The United States is expected to hold the major market share among the 7MM countries during the forecast period (2022-32)
Which country is expected to account for the most significant prevalent cases of Congenital Adrenal Hyperplasia in the 7MM?
The United States is anticipated to account for the highest prevalent cases of Congenital Adrenal Hyperplasia cases among the 7MM during the forecast period
Which are the leading companies in the Congenital Adrenal Hyperplasia Market Landscape?
The key companies in the Congenital Adrenal Hyperplasia Market include Neurocrine Biosciences, Diurnal Limited, Spruce Biosciences, Adrenas Therapeutics, Millendo Therapeutics
What are the key strengths of the Congenital Adrenal Hyperplasia Market Report?
The key strengths of the Congenital Adrenal Hyperplasia Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers, and Market Barriers, along with the upcoming market trends in the Congenital Adrenal Hyperplasia Market

1. Key Insights

2. Report Introduction

3. Congenital Adrenal Hyperplasia Overview at a Glance

3.1. Market Share (%) Distribution of Congenital Adrenal Hyperplasia in 2019

3.2. Market Share (%) Distribution of Congenital Adrenal Hyperplasia in 2032

4. Executive Summary

5. Disease Background and Overview

5.1. Introduction

5.2. Classification

5.3. Causes

5.4. Signs and Symptoms

5.5. Pathophysiology

5.6. Clinical features

5.7. Diagnosis

5.8. Treatment

5.8.1. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Diagnosed Prevalence of CAH

6.3. Assumptions and Rationale

6.4. The United States

6.4.1. Diagnosed Prevalence of CAH in the United States

6.4.2. Age-specific cases of CAH in the United States

6.4.3. Mutations based cases of CAH in the United States

6.4.4. Type-specific cases of Classical CAH in the United States

6.5. EU5

6.5.1. Total Diagnosed Prevalence of CAH in EU5

6.5.2. Germany

6.5.3. Age-specific cases of CAH in Germany

6.5.4. Mutations based cases of CAH in Germany

6.5.5. Type-specific cases of Classical CAH in Germany

6.5.6. France

6.5.7. Age-specific cases of CAH in France

6.5.8. Mutations based cases of CAH in France

6.5.9. Type-specific cases of Classical CAH in France

6.5.10. Italy

6.5.11. Age-specific cases of CAH in Italy

6.5.12. Mutations based cases of CAH in Italy

6.5.13. Type-specific cases of Classical CAH in Italy

6.5.14. Spain

6.5.15. Age-specific cases of CAH in Spain

6.5.16. Mutations based cases of CAH in Spain

6.5.17. Type-specific cases of Classical CAH in Spain

6.5.18. The United Kingdom

6.5.19. Age-specific cases of CAH in the United Kingdom

6.5.20. Mutations based cases of CAH in the United Kingdom

6.5.21. Type-specific cases of Classical CAH in the United Kingdom

6.6. Japan

6.6.1. Diagnosed Prevalence of CAH in Japan

6.6.2. Age-specific cases of CAH in Japan

6.6.3. Mutations based cases of CAH in Japan

6.6.4. Type-specific cases of Classical CAH in Japan

7. Patient Journey

8. Emerging Therapies

8.1. Key Competitors: Emerging Therapies

8.2. Crinecerfont: Neurocrine Biosciences

8.2.1. Product Description

8.2.2. Other Development Activities

8.2.3. Clinical Development

8.2.4. Clinical trials information

8.2.5. Safety and Efficacy

8.2.6. Product Profile

8.2.7. Analyst Comments

8.3. Chronocort: Diurnal Limited

8.3.1. Product Description

8.3.2. Other Developmental Activities

8.3.3. Clinical Development

8.3.4. Clinical trials information

8.3.5. Safety and Efficacy

8.3.6. Product Profile

8.3.7. Analyst Comments

8.4. Tildacerfont: Spruce Biosciences

8.4.1. Product Description

8.4.2. Other Development Activities

8.4.3. Clinical Development

8.4.4. Clinical trials information

8.4.5. Safety and Efficacy

8.4.6. Product Profile

8.4.7. Analyst Comment

8.5. AAV BBP-631: Adrenas Therapeutics

8.5.1. Product Description

8.5.2. Other Development Activities

8.5.3. Clinical Development

8.5.4. Clinical Trials Information

8.5.5. Product Profile

8.5.6. Analyst Comment

9. Other Assets

9.1. ATR-101: Millendo Therapeutics

9.1.1. Product Description

9.1.2. Other Development Activities

9.1.3. Clinical Development

9.1.4. Clinical trials information

9.1.5. Safety and Efficacy

9.1.6. Product Profile

10. Congenital Adrenal Hyperplasia (CAH): 7 Major Market Analysis

10.1. Key Findings

10.2. Market Outlook

10.3. Market Size of Congenital Adrenal Hyperplasia (CAH) in 7MM

10.4. The United States Market Size

10.4.1. Total Market Size of Congenital Adrenal Hyperplasia (CAH) in the United States

10.4.2. Market Size of Congenital Adrenal Hyperplasia (CAH) by Therapies

10.5. EU-5 Market

10.5.1. Total Market Size of Congenital Adrenal Hyperplasia (CAH) in EU-5

10.5.2. Germany

10.5.3. Market Size of Congenital Adrenal Hyperplasia (CAH) by Therapies in Germany

10.5.4. France

10.5.5. Market Size of Congenital Adrenal Hyperplasia (CAH) by Therapies in France

10.5.6. Italy

10.5.7. Market Size of Congenital Adrenal Hyperplasia (CAH) by Therapies in Italy

10.5.8. Spain

10.5.9. Market Size of Congenital Adrenal Hyperplasia (CAH) by Therapies in Spain

10.5.10. The United Kingdom

10.5.11. Market Size of Congenital Adrenal Hyperplasia (CAH) by Therapies in the United Kingdom

10.6. Japan

10.6.1. Total Market Size of Congenital Adrenal Hyperplasia (CAH) in Japan

10.6.2. Market Size of Congenital Adrenal Hyperplasia (CAH) by Therapies in Japan

11. KOL Views

12. SWOT Analysis

13. Unmet Needs

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

List of Table

Table 1: Summary of Congenital adrenal hyperplasia, Epidemiology, and Key Events (2019 to 2032)

Table 2: Clinical Features in Individuals with Classic and Non-classic CAH

Table 3: Summary of the Clinical, Hormonal, and Genetic Features of Steroidogenic Defects

Table 4: Diagnosis of 21-OHD CAH after Infancy Based on 17 OHP Levels

Table 5: Molecular Genetic Testing Used in 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia

Table 6: Enzyme Deficiencies Resulting in CAH

Table 7: Treatment Guidelines

Table 8: Diagnosed Prevalence of CAH in the 7MM (2019 to 2032)

Table 9: Diagnosed Prevalence of CAH in the United States (2019 to 2032)

Table 10: Age-specific cases of CAH in the United States (2019 to 2032)

Table 11: Mutations based cases of CAH in the United States (2019 to 2032)

Table 12: Type-specific cases of Classical CAH in the United States (2019 to 2032)

Table 13: Total Diagnosed Prevalence of CAH in EU5 (2019 to 2032)

Table 14: Age-specific cases of CAH in Germany (2019 to 2032)

Table 15: Mutations based cases of CAH in Germany (2019 to 2032)

Table 16: Type-specific cases of Classical CAH in Germany (2019 to 2032)

Table 17: Age-specific cases of CAH in France (2019 to 2032)

Table 18: Mutations based cases of CAH in France (2019 to 2032)

Table 19: Type-specific cases of Classical CAH in France (2019 to 2032)

Table 20: Age-specific cases of CAH in Italy (2019 to 2032)

Table 21: Mutations based cases of CAH in Italy (2019 to 2032)

Table 22: Type-specific cases of Classical CAH in Italy (2019 to 2032)

Table 23: Age-specific cases of CAH in Spain (2019 to 2032)

Table 24: Mutations based cases of CAH in Spain (2019 to 2032)

Table 25: Type-specific cases of Classical CAH in Spain (2019 to 2032)

Table 26: Age-specific cases of CAH in the United Kingdom (2019 to 2032)

Table 27: Mutations based cases of CAH in the United Kingdom (2019 to 2032)

Table 28: Type-specific cases of Classical CAH in the United Kingdom (2019 to 2032)

Table 29: Diagnosed Prevalence of CAH in Japan (2019 to 2032)

Table 30: Age-specific cases of CAH in Japan (2019 to 2032)

Table 31: Mutations based cases of CAH in Japan (2019 to 2032)

Table 32: Type-specific cases of Classical CAH in Japan (2019 to 2032)

Table 33: AAV BBP-631, Clinical Trial Description, 2022

Table 34: ATR-101, Clinical Trial Description, 2022

Table 35: Total Market Size of Congenital Adrenal Hyperplasia in the 7MM in USD Million (2019–2032)

Table 36: The US Market Size of Congenital Adrenal Hyperplasia, in USD Million (2019–2032)

Table 37: The US Market Size of Congenital Adrenal Hyperplasia by Therapies in USD Million (2019–2032)

Table 38: EU-5 Market Size of Congenital Adrenal Hyperplasia in USD Million (2019–2032)

Table 39: Germany Market Size of Congenital Adrenal Hyperplasia by Therapies in USD Million (2019–2032)

Table 40: France Market Size of Congenital Adrenal Hyperplasia by Therapies in USD Million (2019–2032)

Table 41: Italy Market Size of Congenital Adrenal Hyperplasia by Therapies in USD Million (2019–2032)

Table 42: Spain Market Size of Congenital Adrenal Hyperplasia by Therapies in USD Million (2019–2032)

Table 43: The UK Market Size of Congenital Adrenal Hyperplasia by Therapies in USD Million (2019–2032)

Table 44: Japan Market Size of Congenital Adrenal Hyperplasia in USD Million (2019–2032)

Table 45: Japan Market Size of Congenital Adrenal Hyperplasia by Therapies in USD Million (2019–2032)

List of Figures

Figure 1: Congenital Adrenal Hyperplasia

Figure 2: Classification of CAH

Figure 3: Inheritance of an Autosomal Recessive Disorder from Carrier Parents

Figure 4: Adrenal Steroidogenesis

Figure 5: Different degrees of virilization according to the scale developed by Prader

Figure 6: Total Diagnosed Prevalent Population of CAH in 7MM (2019 to 2032)

Figure 7: Diagnosed Prevalence of CAH in the United States (2019 to 2032)

Figure 8: Age-specific cases of CAH in the United States (2019 to 2032)

Figure 9: Mutations based cases of CAH in the United States (2019 to 2032)

Figure 10: Type-specific cases of Classical CAH in the United States (2019 to 2032)

Figure 11: Total Diagnosed Prevalent Population of CAH in EU5 (2019 to 2032)

Figure 12: Age-specific cases of CAH in Germany (2019 to 2032)

Figure 13: Mutations based cases of CAH in Germany (2019 to 2032)

Figure 14: Type-specific cases of Classical CAH in Germany (2019 to 2032)

Figure 15: Age-specific cases of CAH in France (2019 to 2032)

Figure 16: Mutations based cases of CAH in France (2019 to 2032)

Figure 17: Type-specific cases of Classical CAH in France (2019 to 2032)

Figure 18: Age-specific cases of CAH in Italy (2019 to 2032)

Figure 19: Mutations based cases of CAH in Italy (2019 to 2032)

Figure 20: Type-specific cases of Classical CAH in Italy (2019 to 2032)

Figure 21: Age-specific cases of CAH in Spain (2019 to 2032)

Figure 22: Mutations based cases of CAH in Spain (2019 to 2032)

Figure 23: Type-specific cases of Classical CAH in Spain (2019 to 2032)

Figure 24: Age-specific cases of CAH in the United Kingdom (2019 to 2032)

Figure 25: Mutations based cases of CAH in the United Kingdom (2019 to 2032)

Figure 26: Type-specific cases of Classical CAH in the United Kingdom (2019 to 2032)

Figure 27: Diagnosed Prevalence of CAH in Japan (2019 to 2032)

Figure 28: Age-specific cases of CAH in Japan (2019 to 2032)

Figure 29: Mutations based cases of CAH in Japan (2019 to 2032)

Figure 30: Type-specific cases of Classical CAH in Japan (2019 to 2032)

Figure 31: Total Market Size of Congenital Adrenal Hyperplasia, in USD Million (2019–2032)

Figure 32: The US Market size of Congenital Adrenal Hyperplasia, in USD million (2019–2032)

Figure 33: The US Market Size of Congenital Adrenal Hyperplasia by Therapies (2019–2032)

Figure 34: EU-5 Market Size of Congenital Adrenal Hyperplasia, in USD Million (2019–2032)

Figure 35: Germany Market Size of Congenital Adrenal Hyperplasia by Therapies (2019–2032)

Figure 36: France Market Size of Congenital Adrenal Hyperplasia by Therapies, in USD Million (2019–2032)

Figure 37: Italy Market Size of Congenital Adrenal Hyperplasia by Therapies in USD Million (2019–2032)

Figure 38: Spain Market Size of Congenital Adrenal Hyperplasia by Therapies in USD Million (2019–2032)

Figure 39: The UK Market Size of Congenital Adrenal Hperplasia by Therapies in USD Million (2019–2032)

Figure 40: Japan Market Size of Congenital Adrenal Hyperplasia in USD Million (2019–2032)

Figure 41: Japan Market Size of Congenital Adrenal Hyperplasia by Therapies in USD Million (2019–2032)

Neurocrine Biosciences
Diurnal Limited
Spruce Biosciences
Adrenas Therapeutics
Millendo Therapeutics

 

Forward to Friend

Need A Quote